Cited by 655Medication Adherence and ComplianceDiabetes Management and EducationDiabetes Management and Research

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study

Open access

Peyrot, M., Barnett, A. H., Meneghini, L. F., Schumm‐Draeger, P.‐M.·2012·Diabetic Medicine

DOI 10.1111/j.1464-5491.2012.03605.xPMC PMC3433794

Open this paper in CoChat — free account Open PDF

Abstract

AIMS: To examine patient and physician beliefs regarding insulin therapy and the degree to which patients adhere to their insulin regimens. METHODS: Internet survey of 1250 physicians (600 specialists, 650 primary care physicians) who treat patients with diabetes and telephone survey of 1530 insulin-treated patients (180 with Type 1 diabetes, 1350 with Type 2 diabetes) in China, France, Japan, Germany, Spain, Turkey, the UK or the USA. RESULTS: One third (33.2%) of patients reported insulin omission/non-adherence at least 1 day in the last month, with an average of 3.3 days. Three quarters (72.5%) of physicians report that their typical patient does not take their insulin as prescribed, with a mean of 4.3 days per month of basal insulin omission/non-adherence and 5.7 days per month of prandial insulin omission/non-adherence. Patients and providers indicated the same five most common reasons for insulin omission/non-adherence: too busy; travelling; skipped meals; stress/emotional problems; public embarrassment. Physicians reported low patient success at initiating insulin in a timely fashion and adjusting insulin doses. Most physicians report that many insulin-treated patients do not have adequate glucose control (87.6%) and that they would treat more aggressively if not for concern about hypoglycaemia (75.5%). Although a majority of patients (and physicians) regard insulin treatment as restrictive, more patients see insulin treatment as having positive than negative impacts on their lives. CONCLUSIONS: Glucose control is inadequate among insulin-treated patients, in part attributable to insulin omission/non-adherence and lack of dose adjustment. There is a need for insulin regimens that are less restrictive and burdensome with lower risk of hypoglycaemia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2012.03605.x

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

FIGURE 1 Physician report: patient success with insulin treatment tasks (n = 1250)*†. *Percentage of physicians reporting that their patients are very successful (vs. somewhat successful, not very successful, not at all successful, ‘don’t know’). †Specialists and primary care physicians not significantly different for any measureCC BY · PubMed Central

FIGURE 2 Patient reports: impact of insulin treatment on life domains in patients with Type 1 (non-hatched) and Type 2 (hatched) diabetes mellitus (n = 1530). *Positive and negative responses differ significantly (P < 0.05); †reports from patients with Type 1 and Type 2 diabetes differ significantly (P < 0.05).CC BY · PubMed Central

FIGURE 3 Physician beliefs about insulin treatment (n = 1250). *Strongly agree or somewhat agree (vs. strongly disagree, somewhat disagree, neither, ‘don’t know’); †strongly agree or somewhat agree (vs. strongly disagree, somewhat disagree)CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
A systematic review of adherence with medications for diabetes
Cramer, J. A. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1218 · Cited by 1,203
Psychosocial problems and barriers to improved diabetes management: results of the Cross‐National Diabetes Attitudes, Wishes and Needs (DAWN) Study
Peyrot, M., Rubin, R. R., Lauritzen, T., Snoek, F. J., Matthews, D. R., & Skovlund, S. E. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01644.x · Cited by 931
Self-citation
Resistance to Insulin Therapy Among Patients and Providers
Peyrot, M. F., Rubin, R. R., Lauritzen, T., Skovlund, S. E., Snoek, F. J., Matthews, D. R., Landgraf, R., Kleinebreil, L., & Panel, O. B. O. T. I. D. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.11.2673 · Cited by 784
Self-citation
Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus
Morris, A. D., Boyle, D. I., McMahon, A. D., Greene, S. A., MacDonald, T. M., & Newton, R. W. (1997) · The Lancet · doi:10.1016/s0140-6736(97)06234-x · Cited by 507
Correlates of Insulin Injection Omission
Peyrot, M., Rubin, R. R., Kruger, D. F., & Travis, L. B. (2010) · Diabetes Care · doi:10.2337/dc09-1348 · Cited by 407
Self-citation
Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus
Rubin, R. R. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.04.012 · Cited by 403
Psychological insulin resistance: patient beliefs and implications for diabetes management
Brod, M. I., Kongsø, J. H., Alolga, S. L., & Christensen, T. L. (2008) · Quality of Life Research · doi:10.1007/s11136-008-9419-1 · Cited by 238
Insulin therapy for type 2 diabetes.
Swinnen, S. G., Hoekstra, J. B., & DeVries, J. H. (2009) · Diabetes Care · doi:10.2337/dc09-s318 · Cited by 181
Transition to insulin in Type 2 diabetes: family physicians' misconception of patients' fears contributes to existing barriers
Nakar, S., Yitzhaki, G., Rosenberg, R., & Vinker, S. (2007) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2006.02.004 · Cited by 159

Show all 22 references

Sorted by citations

Items 101–200 of 655

A global systematic overview of socioeconomic factors associated with antidiabetic medication adherence in individuals with type 2 diabetes
Studer, C. M., Linder, M., & Pazzagli, L. (2023) · Journal of Health Population and Nutrition · doi:10.1186/s41043-023-00459-2 · Cited by 56
Negative appraisals of insulin therapy are common among adults with Type 2 diabetes using insulin: Results from Diabetes MILES – Australia cross‐sectional survey
Holmes‐Truscott, E., Skinner, T. C., Pouwer, F., & Speight, J. (2015) · Diabetic Medicine · doi:10.1111/dme.12729 · Cited by 44
Can Smart Pens Help Improve Diabetes Management?
Sy, S. L., Munshi, M. N., & Toschi, E. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820965600 · Cited by 46
Efficacy and safety of once‐monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo‐controlled, 16‐week randomized dose‐finding study
Del Prato, S., Kang, J., Trautmann, M. E., Stewart, J., Sorli, C. H., Derwahl, M., Soto, A., & Yoon, K. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14020 · Cited by 43
A E uropean, multicentre, retrospective, non‐interventional study ( EU‐TREAT ) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes
Siegmund, T., Tentolouris, N., Knudsen, S. T., Lapolla, A., Prager, R., Phan, T., Wolden, M. L., Schultes, B., & for the EU‐TREAT study group (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13149 · Cited by 43
Take Control: A randomized trial evaluating the efficacy and safety of self‐ versus physician‐managed titration of insulin glargine 300 U/mL in patients with uncontrolled type 2 diabetes
Russell-Jones, D. L., Dauchy, A., Delgado, E., Dimitriadis, G., Frandsen, H., Popescu, L., Schultes, B., Strojek, K., Bonnemaire, M., de Climens, A. R., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13697 · Cited by 43
Flexible insulin dosing improves health-related quality-of-life (HRQoL): a time trade-off survey
Evans, M., Jensen, H. H., Bøgelund, M., Gundgaard, J., Chubb, B., & Khunti, K. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2013.846262 · Cited by 42
Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease
Gale, R. P., Scanlon, P. H., Evans, M., Ghanchi, F. D., Yang, Y. C., Silvestri, G., Freeman, M., Maisey, A., & Napier, J. (2017) · Eye · doi:10.1038/eye.2017.53 · Cited by 42
Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes ( EDITION 4)
Home, P. D., Bergenstal, R. M., Bolli, G. B., Ziemen, M., Rojeski, M., Espinasse, M., & Riddle, M. C. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13048 · Cited by 42
Insulin Delivery Using Dynamic Covalent Boronic Acid/Ester‐Controlled Release
Banach, Ł., Williams, G. T., & Fossey, J. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100118 · Cited by 41
Therapeutic Inertia and Delays in Insulin Intensification in Type 2 Diabetes: A Literature Review
Gavin, J. R., Abaniel, R. M., & Virdi, N. S. (2023) · Diabetes Spectrum · doi:10.2337/ds22-0084 · Cited by 45
Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy
Owens, D. R., Traylor, L., Mullins, P. R., & Landgraf, W. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.10.022 · Cited by 43
Prevalence and correlation of glycemic control achievement in patients with type 2 diabetes in Iraq: A retrospective analysis of a tertiary care database over a 9-year period
Mansour, A. A., Alibrahim, N. T. Y., Alidrisi, H. A., Alhamza, A. H. A., Almomin, A., Zaboon, I. A., Kadhim, M. B., Hussein, R. N., Nwayyir, H. A., Mohammed, A. G., et al. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.03.008 · Cited by 52
The determinants of anti-diabetic medication adherence based on the experiences of patients with type 2 diabetes
Dehdari, L., & Dehdari, T. (2019) · Archives of Public Health · doi:10.1186/s13690-019-0347-z · Cited by 46
Comparing patient preferences and healthcare provider recommendations with the pen versus vial-and-syringe insulin delivery in patients with type 2 diabetes
Ahmann, A., Szeinbach, S. L., Gill, J., Traylor, L., & Garg, S. K. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0172 · Cited by 39
Efficacy and safety of insulin glargine 300 U/ mL vs insulin degludec in patients with type 2 diabetes: A randomized, open‐label, cross‐over study using continuous glucose monitoring profiles
Kawaguchi, Y., Sawa, J., Sakuma, N., & Kumeda, Y. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12884 · Cited by 41
Implementation of Basal–Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen
Bergenstal, R. M., Peyrot, M. F., Dreon, D. M., Aroda, V. R., Bailey, T. S., Brazg, R., Frías, J. P., Johnson, M. L., Klonoff, D. C., Kruger, D. F., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0298 · Cited by 40
Self-citation
U300, a novel long-acting insulin formulation
Sutton, G. L., Minguet, J., Ferrero, C., & Bramlage, P. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.970633 · Cited by 38
Clinical, economic, and patient-reported benefits of connected insulin pen systems: a systematic literature review
Cranston, I., Jamdade, V., Liao, B., & Newson, R. S. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02478-1 · Cited by 37
The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real‐world setting
Meneghini, L., Mauricio, D., Orsi, E., Lalic, N. M., Cali, A. M. G., Westerbacka, J., Stella, P., Candelas, D. C., Pilorget, V., Perfetti, R., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13673 · Cited by 40
Self-citation
Leveraging advances in diabetes technologies in primary care: a narrative review
Bode, B. W., King, A., Russell-Jones, D. L., & Billings, L. K. (2021) · Annals of Medicine · doi:10.1080/07853890.2021.1931427 · Cited by 41
Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
Gough, S. C. L., Jain, R., & Woo, V. C. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2016.1113129 · Cited by 37
Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes
Rodbard, H. W., Buse, J. B., Woo, V. C., Vilsbøll, T., Langbakke, I. H., Kvist, K., & Gough, S. C. L. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12574 · Cited by 36
Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents
Philis‐Tsimikas, A., Prato, S. D., Satman, İ., Bhargava, A., Dharmalingam, M., Skjøth, T. V., Rasmussen, S., & Garber, A. J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12115 · Cited by 36
New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus
Goldman, J. D., & White, J. R. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015597915 · Cited by 36
Measuring insulin adherence among adults with type 2 diabetes
Osborn, C. Y., & Gonzalez, J. S. (2016) · Journal of Behavioral Medicine · doi:10.1007/s10865-016-9741-y · Cited by 36
Cultural Differences and Considerations When Initiating Insulin
Rebolledo, J. A., & Arellano, R. (2016) · Diabetes Spectrum · doi:10.2337/diaspect.29.3.185 · Cited by 41
Improved Glycemic Control Observed in Children with Type 1 Diabetes Following the Introduction of Smart Insulin Pens: A Real-World Study
Adolfsson, P., Björnsson, V., Hartvig, N. V., Kaas, A., Møller, J. B., & Lange, E. O. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01177-w · Cited by 36
Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues
Kalra, S. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0067-x · Cited by 35
Effect of Adherence and Insulin Delivery System on Clinical and Economic Outcomes among Patients with Type 2 Diabetes Initiating Insulin Treatment
Ayyagari, R., Wei, W., Cheng, D., Pan, C., Signorovitch, J., & Wu, E. Q. (2015) · Value in Health · doi:10.1016/j.jval.2014.12.016 · Cited by 35
What are the barriers faced by patients using insulin? A qualitative study of Malaysian health care professionals’ views
Lee, Y. K., Ng, C. J., Lee, P. Y., Khoo, E. M., Khatijah, Low, Azah, & Chen (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s36791 · Cited by 36
Hypoglycemia After Initiation of Basal Insulin in Patients with Type 2 Diabetes in the United States: Implications for Treatment Discontinuation and Healthcare Costs and Utilization
Dalal, M. R., Kazemi, M. R., Ye, F., & Xie, L. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0592-x · Cited by 36
Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes
Mocarski, M., Yeaw, J., Divino, V. M., DeKoven, M., Guerrero, G., Langer, J., & Thorsted, B. L. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.17218 · Cited by 34
Are bedtime nutritional strategies effective in preventing nocturnal hypoglycaemia in patients with type 1 diabetes?
Desjardins, K., Brazeau, A., Strychar, I. M., & RABASA-LHORET, R. P. R. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12232 · Cited by 33
Barriers to Diabetes Self-Management in a Subset of New Zealand Adults with Type 2 Diabetes and Poor Glycaemic Control
Chepulis, L. M., Morison, B. J., Cassim, S., Norman, K., Keenan, R., Paul, R. G., & Lawrenson, R. A. (2021) · Journal of Diabetes Research · doi:10.1155/2021/5531146 · Cited by 32
Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus
Atkin, S. L., Javed, Z., & Fulcher, G. R. (2015) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315608646 · Cited by 34
The use of continuous glucose monitoring in people living with obesity, intermediate hyperglycemia or type 2 diabetes
Battelino, T., Lalic, N. M., Hussain, S., Ceriello, A., Majanović, S. K., Davies, S., Topsever, P., Heverly, J., Ulivi, F., Brady, K., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112111 · Cited by 34
Will the next generation of basal insulins offer clinical advantages?
Garber, A. J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12219 · Cited by 32
Stigma among workers attending a hospital specialist diabetes clinic
Lee, S.-M., Lim, L. C., & Koh, D. S. Q. (2014) · Occupational Medicine · doi:10.1093/occmed/kqu150 · Cited by 32
Estimating the impact of changes in HbA1c, body weight and insulin injection regimen on health related quality-of-life: a time trade off study
Ridderstråle, M., Evans, L. M., Jensen, H. H., Bøgelund, M., Jensen, M. M., Ericsson, Å., & JENDLE, J. H. (2016) · Health and Quality of Life Outcomes · doi:10.1186/s12955-016-0411-0 · Cited by 32
Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden
Ericsson, Å., & Lundqvist, A. (2017) · Applied Health Economics and Health Policy · doi:10.1007/s40258-016-0301-y · Cited by 31
Therapeutic Inertia in People With Type 2 Diabetes in Primary Care: A Challenge That Just Won’t Go Away
Zhu, N. A., & Harris, S. B. (2020) · Diabetes Spectrum · doi:10.2337/ds19-0016 · Cited by 34
The prevalence of adherence to insulin therapy in patients with diabetes: A systematic review and meta-analysis
Boonpattharatthiti, K., Saensook, T., Neelapaijit, N., Sakunrag, I., Krass, I., & Dhippayom, T. (2023) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2023.11.009 · Cited by 37
Complementing Insulin Therapy to Achieve Glycemic Control
Barnett, A. H. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0039-y · Cited by 33
Self-citation
Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting
Davies, M. J., Glah, D. R., Chubb, B., Konidaris, G., & McEwan, P. C. (2016) · PharmacoEconomics · doi:10.1007/s40273-016-0433-9 · Cited by 30
Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
Lau, I. T., Lee, K. F., So, W. Y., Tan, K. C. B., & Yeung, M. W. (2017) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s131358 · Cited by 31
Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes
Blonde, L., Anderson, J. E., Chava, P., & Dendy, J. A. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1541790 · Cited by 33
Engineered insulin-polycation complexes for glucose-responsive delivery with high insulin loading
Volpatti, L. R., Burns, D. M., Basu, A., Langer, R., & Anderson, D. G. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.08.017 · Cited by 31
Safety and Effectiveness of MiniMed TM 780G Advanced Hybrid Closed-Loop Insulin Intensification in Adults with Insulin-Requiring Type 2 Diabetes
Bhargava, A., Bergenstal, R. M., Warren, M., Thrasher, J. R., Dempsey, M. A., Bode, B. W., LaRocque, J., Carlson, A. L., Keiter, A., Ma, H., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0586 · Cited by 31
Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300U/mL compared with glargine 100U/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised 12-month trial including 6-month extension)
Matsuhisa, M., Koyama, M., Cheng, X., Sumi, M., Riddle, M. C., Bolli, G. B., & Hirose, T. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.10.002 · Cited by 30
Intuitive eating is associated with glycemic control in type 2 diabetes
Soares, F. L. P., Ramos, M. H., Gramelisch, M., Silva, R. D. P. P., Batista, J. D. S., Cattafesta, M., & Salaroli, L. B. (2020) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-020-00894-8 · Cited by 30
Glucose- and pH-Responsive Supramolecular Polymer Vesicles Based on Host–Guest Interaction for Transcutaneous Delivery of Insulin
Lin, Y., Hu, W., Bai, X., Ju, Y., Cao, C., Zou, S., Tong, Z., Cen, C., Jiang, G., & Kong, X. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00813 · Cited by 30
Which Aspect of Patient–Provider Relationship Affects Acceptance and Adherence of Insulin Therapy in Type 2 Diabetes Mellitus? A Qualitative Study in Primary Care
Mathew, B. K., Roza, J. G. D., Liu, C., Goh, L. J., Ooi, C. W., Chen, E., Poon, S., & Tang, W. E. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s344607 · Cited by 33
Descriptions of health states associated with increasing severity and frequency of hypoglycemia: a patient-level perspective
Harris, S. B., Khunti, K. K., Landin‐Olsson, M., Galbo-Jørgensen, Bøgelund, Chubb, Gundgaard, & Evans, M. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s46805 · Cited by 30
Adherence to insulin treatment in diabetes: can it be improved?糖尿病患者使用胰岛素治疗的依从性：它能够得到改善吗？
Doggrell, S. A., & Chan, V. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12212 · Cited by 29
IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy
Freemantle, N., Mamdani, M., Vilsbøll, T., Kongsø, J. H., Kvist, K., & Bain, S. C. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0142-y · Cited by 29
Treatment intensification with insulin pumps and other technologies in patients with type 2 diabetes: results of a physician survey in the United States
Grunberger, G., Sze, D., Ermakova, A., Sieradzan, R., Oliveria, T., & Miller, E. M. (2020) · Clinical Diabetes · doi:10.2337/cd19-0008 · Cited by 28
An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin
Evans, M., Billings, L. K., Håkan‐Bloch, J., Slothuus, U., Abrahamsen, T. J., Andersen, A., & Jansen, J. P. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1409228 · Cited by 28
Comparison of insulin glargine 300 U/ mL and insulin degludec using flash glucose monitoring: A randomized cross‐over study
Yamabe, M., Kuroda, M., Hirosawa, Y., Kamino, H., Ohno, H., & Yoneda, M. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12894 · Cited by 29
Healthcare Professionals’ Views of Factors Influencing Diabetes Self-Management and the Utility of a mHealth Application and Its Features to Support Self-Care
Yoon, S., Ng, J. H., Kwan, Y. H., & Low, L. L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.793473 · Cited by 32
Factors influencing inter‐day glycemic variability in diabetic outpatients receiving insulin therapy
Mori, H., Okada, Y., Kurozumi, A., Narisawa, M., & Tanaka, Y. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12551 · Cited by 28
Switching to degludec from other basal insulins is associated with reduced hypoglycemia rates: A prospective study
Fadini, G. P., Feher, M., Hansen, T. K., de Valk, H. W., Koefoed, M. M., Wolden, M., Zimmermann, E., & Jendle, J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-01021 · Cited by 27
Efficacy and Safety of Insulin Degludec 200 U/mL and Insulin Degludec 100 U/mL in Patients with Type 2 Diabetes (Begin: Compare)
Bode, B. W., CHAYKIN, L. B., Sussman, A., Warren, M., Niemeyer, M., Rabøl, R., & Rodbard, H. W. (2014) · Endocrine Practice · doi:10.4158/ep13411.or · Cited by 27
Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice—a case-based evaluation
Evans, M., McEwan, P. C., & FOOS, V. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.975234 · Cited by 27
Titratable fixed‐ratio combination of basal insulin plus a glucagon‐like peptide‐1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes
Peralta, F. G., Al‐Ozairi, E., Jude, E. B., Li, X., & Rosenstock, J. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14365 · Cited by 29
Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial
Billings, L. K., Andreozzi, F., Frederiksen, M., Gourdy, P., Gowda, A., Ji, L., Pletsch‐Borba, L., Suzuki, R., Unnikrishnan, A. G., & Vianna, A. G. D. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00052-x · Cited by 26
Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes
Christiansen, J. S., NISKANEN, L. K., Rasmussen, S., Johansen, T., & Fulcher, G. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12355 · Cited by 26
Insulin Matters: A Practical Approach to Basal Insulin Management in Type 2 Diabetes
Berard, L., Antonishyn, N., Arcudi, K., Blunden, S., CHENG, A. Y. Y., Goldenberg, R., Harris, S. B., Jones, S., Mehan, U., Morrell, J., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0375-7 · Cited by 25
Insulin–Dendrimer Nanocomplex for Multi‐Day Glucose‐Responsive Therapy in Mice and Swine
Xian, S., Xiang, Y., Liu, D., Fan, B., Mitrová, K., Ollier, R. C., Su, B., Alloosh, M. A., Jiráček, J., Sturek, M. S., et al. (2023) · Advanced Materials · doi:10.1002/adma.202308965 · Cited by 26
Approach to assessing the economic impact of insulin‐related hypoglycaemia using the novel Local Impact of Hypoglycaemia Tool
Parekh, W., Ashley, D., Chubb, B., Gillies, H., & Evans, M. (2015) · Diabetic Medicine · doi:10.1111/dme.12771 · Cited by 26
Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden
Ericsson, Å., & Fridhammar, A. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1614009 · Cited by 25
A Practitioner’s Toolkit for Insulin Motivation in Adults with Type 1 and Type 2 Diabetes Mellitus: Evidence-Based Recommendations from an International Expert Panel
Kalra, S., Bajaj, S., Sharma, S. K., Priya, G., Baruah, M. P., Sanyal, D., Das, S., Chaudhury, T., Gangopadhyay, K. K., Das, A. K., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00764-7 · Cited by 28
Technology in the Management of Type 1 and Type 2 Diabetes Mellitus: Recent Status and Future Prospects
Biswas, T., Behera, B. K., & Madhu, N. R. (2023) · Springer eBooks · doi:10.1007/978-981-19-0027-3_6 · Cited by 33
Further investigation of the psychometric properties of the insulin treatment appraisal scale among insulin-using and non-insulin-using adults with type 2 diabetes: results from diabetes MILES – Australia
Holmes‐Truscott, E., Pouwer, F., & Speight, J. (2014) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-12-87 · Cited by 25
Type 2 Diabetes Mellitus: Outpatient Insulin Management.
Howard-Thompson, A., Khan, M., Jones, M., & George, C. M. (2018) · PubMed · Cited by 25
Model predictive control for dose guidance in long acting insulin treatment of type 2 diabetes
Aradóttir, T. B., Boiroux, D., Bengtsson, H. L., Kildegaard, J., Jensen, M. L., Jørgensen, J. B., & Poulsen, N. K. (2019) · IFAC Journal of Systems and Control · doi:10.1016/j.ifacsc.2019.100067 · Cited by 25
Insulin Icodec Weekly: A Basal Insulin Analogue for Type 2 Diabetes
BAJAJ, H. S., LMC Diabetes & Endocrinology, B., Goldenberg, R. M., & LMC Diabetes & Endocrinology, C. (2023) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2023.19.1.4 · Cited by 25
Incidence, worry and discussion about dosing irregularities and self-treated hypoglycaemia amongst HCPs and patients with type 2 diabetes: results from the UK cohort of the Global Attitudes of Patient and Physicians (GAPP2) survey
Munro, N. M., & Barnett, A. H. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12388 · Cited by 24
Self-citation
Flexibly timed once‐daily dosing with degludec: a new ultra‐long‐acting basal insulin
Josse, R. G., & Woo, V. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12114 · Cited by 24
Patients' with type 2 diabetes willingness to pay for insulin therapy and clinical outcomes
Feher, M. D., Brazier, J. E., Schaper, N. C., Vega-Hernandez, G., Nikolajsen, A., & Bøgelund, M. (2016) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000192 · Cited by 26
Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study
Gupta, S., Wang, H., SKOLNIK, N., Tong, L., Liebert, R., Lee, L. K., Stella, P., Cali, A. M. G., & Preblick, R. (2018) · Advances in Therapy · doi:10.1007/s12325-017-0651-3 · Cited by 26
iGlarLixi: A New Once-Daily Fixed-Ratio Combination of Basal Insulin Glargine and Lixisenatide for the Management of Type 2 Diabetes
Hinnen, D., & Strong, J. L. (2018) · Diabetes Spectrum · doi:10.2337/ds17-0014 · Cited by 24
Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus
Giorgino, F., Caruso, I., & Napoli, R. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108478 · Cited by 24
Pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in individuals with type 1 diabetes
Hövelmann, U., Engberg, S., Heise, T., Kristensen, N. R., Nørgreen, L., Zijlstra, E., & Ribel‐Madsen, R. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15510 · Cited by 27
The impact of insulin therapy and attitudes towards insulin intensification among adults with type 2 diabetes: A qualitative study
Holmes‐Truscott, E., Browne, J. L., & Speight, J. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.03.027 · Cited by 24
Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications
Wysham, C., Campos, C., & Kruger, D. F. (2018) · Clinical Diabetes · doi:10.2337/cd17-0064 · Cited by 23
Basal insulin therapy: Unmet medical needs in Asia and the new insulin glargine in diabetes treatment
Tien, K., Hung, Y., Chen, J., Chen, C., Wang, C., Hwu, C., Huang, Y., Hsiao, P., Tu, S., Wang, C., et al. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12984 · Cited by 23
Microfluidic-based systems for the management of diabetes
Zhang, S., & Staples, A. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01569-y · Cited by 22
Clinical inertia in basal insulin-treated patients with type 2 diabetes – Results from a retrospective database study in Japan (JDDM 43)
Satoh, J., Andersen, M., Hansen, B. B., Thorsted, B. L., Tutkunkardas, D., Zacho, M., & Maegawa, H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198160 · Cited by 19
New Digital Health Technologies for Insulin Initiation and Optimization for People With Type 2 Diabetes
Kerr, D. E., Edelman, S. V., Vespasiani, G., & Khunti, K. K. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.04.006 · Cited by 23
Increased risk of severe hypoglycemic events with increasing frequency of non-severe hypoglycemic events in patients with type 1 and type 2 diabetes
Sreenan, S., Andersen, M., Thorsted, B. L., Wolden, M. L., & Evans, M. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0075-x · Cited by 21
A real‐world study of treatment patterns and outcomes in US managed‐care patients with type 2 Diabetes initiating injectable therapies
Wei, W., Buysman, E. K., Grabner, M., Xie, L., Brekke, L. N., Ke, X., Chu, J. W., & LEVIN, P. A. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12828 · Cited by 21
Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns
Demir, T., Turan, S., Ünlühızarcı, K., Topaloğlu, O., Tükek, T., & Yavuz, D. G. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.616514 · Cited by 22
Patient safety and minimizing risk with insulin administration – role of insulin degludec
Atkin, S. L., & Aye, M. (2014) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s59566 · Cited by 22
Attitudes of patients and physicians to insulin therapy in Japan: an analysis of the Global Attitude of Patients and Physicians in Insulin Therapy study
Harashima, S., Nishimura, A., & Inagaki, N. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1260547 · Cited by 21
Combination Therapy With DPP-4 Inhibitors and Insulin in Patients With Type 2 Diabetes Mellitus: What Is the Evidence?
Charbonnel, B. H., Schweizer, A., & Dejager, S. (2013) · Hospital Practice · doi:10.3810/hp.2013.04.1059 · Cited by 20
The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?
Maiorino, M. I., Petrizzo, M., Capuano, A., Giugliano, D., & Esposito, K. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.895812 · Cited by 20
Improved patient‐reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial
Polonsky, W. H., Giorgino, F., Rosenstock, J., Whitmire, K., Lew, E., Coudert, M., Alvarez, A., Nicholls, C. J., & McCrimmon, R. J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14822 · Cited by 20
A psychophysical account of patient non-adherence to medical prescriptions. The case of insulin dose adjustment
Reach, G. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.08.009 · Cited by 21
Evaluation of preference for a novel durable insulin pen with memory function among patients with diabetes and health care professionals
Mikkelsen, K. H., Klausmann, Hramiak, Qvist, & Guo, X. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s41929 · Cited by 20

Authors: Peyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐.
Affiliations: Johns Hopkins University (US)
Heart of England NHS Foundation Trust (GB)
University of Miami (US)
München Klinik Bogenhausen (DE)
Corresponding author: Peyrot, M.
ORCID: Peyrot, M.
Meneghini, L. F.
Venue: Diabetic Medicine
Publisher: Wiley
Published: 2012-04-16
Volume: 29
Issue: 5
Pages: 682-689
ISSN: 0742-3071 (ISSN-L)
1464-5491
DOI: 10.1111/j.1464-5491.2012.03605.x
PMC: PMC3433794
OpenAlex: W1613501644
Cited by: 655
References: 22
Citations by year: 2026: 29 · 2025: 41 · 2024: 61 · 2023: 43 · 2022: 42 · 2021: 43 · 2020: 53 · 2019: 49 · 2018: 52 · 2017: 48 · 2016: 52 · 2015: 50 · 2014: 46 · 2013: 35 · 2012: 8
FWCI: 38.62
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Diabetic Medicine (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
Topics: Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords: insulin therapy, insulin adherence, insulin omission, barriers to adherence, patient beliefs, physician beliefs, type 1 diabetes, type 2 diabetes, glycemic control, hypoglycemia, basal insulin, prandial insulin, insulin dose adjustment
MeSH terms: Assessment of Medication Adherence, Blood Glucose, China, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Female, France, Germany, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Japan, Male, Middle Aged, Spain, Turkey, United States, Health Behavior, Drug Monitoring, Medication Adherence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks